Met Life Investment Management, LLC Puma Biotechnology, Inc. Transaction History
Met Life Investment Management, LLC
- $20.1 Billion
- Q3 2025
A detailed history of Met Life Investment Management, LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 14,545 shares of PBYI stock, worth $71,997. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,545
Previous 27,158
46.44%
Holding current value
$71,997
Previous $93,000
20.43%
% of portfolio
0.0%
Previous 0.0%
Shares
25 transactions
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.1MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...